Improved Responses in Colorectal Cancer With Encorafenib/Cetuximab Plus Chemo
Results from the phase 3 BREAKWATER trial (NCT04607421) shared at the 2025 Gastrointestinal Cancer Symposium demonstrated that encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 chemotherapy (fluorouracil, leucovorin, and oxaliplatin) elicited an …